Ipsen: lung cancer drug fails trial

(CercleFinance.com) - Ipsen has announced that the phase III Resilient study, evaluating its Onivyde in patients with small cell lung cancer, has failed to meet its primary endpoint of overall survival compared to Topotecan.


However, the secondary endpoint, objective response rate, was found to double in favour of Onivyde. Safety and tolerability were in line with the known profile and no new safety issues were identified.

Ipsen adds that the detailed results of this clinical study will be presented at an upcoming medical conference and will be communicated to the regulatory agency.


Copyright (c) 2022 CercleFinance.com. All rights reserved.